Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

Phase 3 Completed 133 enrolled Antares Pharma Inc.

NaSingle-groupOpen-labelTreatment

Summary

Evaluation of safety of a concentration controlled testosterone enanthate QuickShot Testosterone regimen administered subcutaneously once each week to adult males with hypogonadism.

Timeline

Start: 2015-07
Primary completion: 2016-06
Completion: 2016-06

Publications

Gittelman M, Jaffe JS, Kaminetsky JC. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study. J Sex Med. 2019 Nov;16(11):1741-1748. doi: 10.1016/j.jsxm.2019.08.013. Epub 2019 Sep 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Testosterone Enanthate	Small molecule	50 mg	Subcutaneous
Subject	Testosterone Enanthate	Small molecule	75 mg	Subcutaneous
Subject	Testosterone Enanthate	Small molecule	100 mg	Subcutaneous

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

Summary

Timeline

Publications

Drugs

Indications